Bek, Stephan,Brachat, Arndt,Hueber, Wolfgang,Li, Yali,Wang, Ying,Yelensky, Roman
申请号：
AU2013249232
公开号：
AU2013249232A1
申请日:
2013.04.18
申请国别(地区):
AU
年份:
2014
代理人:
摘要：
The disclosure is directed to novel personalized therapies and methods for treating ankylosing spondylitis (AS). Specifically, this disclosure relates to methods of treating a patient having AS by selectively administering an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab, to the AS patient on the basis of that patient being predisposed to have a favorable response to treatment with the IL-17 antagonist. Also disclosed herein are diagnostic methods and transmittable forms of information useful in predicting the likelihood that a patient having AS will respond to treatment with an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab.
